Is MSTR Stock Fundamentally Misunderstood?
Software firm turned Bitcoin treasury Strategy (NASDAQ:MSTR) has made waves…
Buy
66
TERN Quote, Financials, Valuation and Earnings
Last price:
$3.93
Seasonality move
:
15.3%
Day range:
$3.87 - $4.10
52-week range:
$1.87 - $11.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.10x
Volume:
770.9K
Avg. volume:
840.3K
1-year change:
-44.07%
Market cap:
$358.1M
Revenue:
--
EPS (TTM):
-$1.09
Analysts' Opinion
-
Consensus RatingTerns Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $19.14, Terns Pharmaceuticals has an estimated upside of 366.9% from its current price of $4.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing 100% downside risk from its current price of $4.10.
Fair Value
-
According to the consensus of 7 analysts, Terns Pharmaceuticals has 366.9% upside to fair value with a price target of $19.14 per share.
TERN vs. S&P 500
-
Over the past 5 trading days, Terns Pharmaceuticals has overperformed the S&P 500 by 16.39% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Terns Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Terns Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Terns Pharmaceuticals reported revenues of --.
Earnings Growth
-
Terns Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Terns Pharmaceuticals reported earnings per share of -$0.26.
Enterprise value:
23.8M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.33x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$72.4M | -$103.8M | -$103.9M | -$25.4M | -$27.4M | |
| EBITDA | -$71.4M | -$103M | -$103M | -$25.2M | -$27.3M | |
| Diluted EPS | -$1.59 | -$1.26 | -$1.09 | -$0.30 | -$0.26 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $198M | $154.1M | $299.7M | $245.9M | $337.7M | |
| Total Assets | $199.2M | $156.7M | $301.3M | $246.8M | $339.3M | |
| Current Liabilities | $8.4M | $6.2M | $12.1M | $8.8M | $10.9M | |
| Total Liabilities | $9.2M | $8M | $13.6M | $10M | $13.3M | |
| Total Equity | $190M | $148.7M | $287.7M | $236.7M | $326M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$50.2M | -$75.8M | -$71.7M | -$22.8M | -$24.4M | |
| Cash From Investing | -$3.8M | -$57.9M | -$18.4M | $8M | $2M | |
| Cash From Financing | $194.7M | $14.4M | $164.1M | -- | $68K | |
| Free Cash Flow | -$50.2M | -$75.9M | -$71.7M | -$22.8M | -$24.4M | |
TERN
Sector
Market Cap
$358.1M
$33.4M
Price % of 52-Week High
35.97%
47.1%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-44.07%
-36.6%
Beta (5-Year)
--
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.67
200-day SMA
Sell
Level
$5.28
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$3.27
Relative Strength Index (RSI14)
Buy
Level
69.91
ADX Line
Neutral
Level
0
Williams %R
Sell
Level
-16
50-day SMA
Buy
Level
$2.94
MACD (12, 26)
Buy
Level
0.25
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
--
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
Stock Forecast FAQ
In the current month, TERN has received 5 Buy ratings 2 Hold ratings, and 0 Sell ratings. The TERN average analyst price target in the past 3 months is $19.14.
-
Where Will Terns Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Terns Pharmaceuticals share price will rise to $19.14 per share over the next 12 months.
-
What Do Analysts Say About Terns Pharmaceuticals?
Analysts are divided on their view about Terns Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Terns Pharmaceuticals is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is Terns Pharmaceuticals's Price Target?
The price target for Terns Pharmaceuticals over the next 1-year time period is forecast to be $19.14 according to 7 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is TERN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Terns Pharmaceuticals is a Buy. 5 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TERN?
You can purchase shares of Terns Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Terns Pharmaceuticals shares.
-
What Is The Terns Pharmaceuticals Share Price Today?
Terns Pharmaceuticals was last trading at $3.93 per share. This represents the most recent stock quote for Terns Pharmaceuticals. Yesterday, Terns Pharmaceuticals closed at $4.10 per share.
-
How To Buy Terns Pharmaceuticals Stock Online?
In order to purchase Terns Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet or Amazon the Better Buy?
Alphabet (NASDAQ:GOOG) and Amazon (NASDAQ:AMZN) are two of the mega-cap…
Why Did Ken Griffin Buy Sweetgreen Stock?
In Q1, Ken Griffin’s Citadel Advisors purchased nearly 1.3 million…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
73
OKLO alert for Jun 12
Oklo [OKLO] is down 5.6% over the past day.
Buy
87
SMR alert for Jun 12
NuScale Power [SMR] is down 2.96% over the past day.
Buy
53
PLAY alert for Jun 12
Dave & Buster's Entertainment [PLAY] is up 0.69% over the past day.
